{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"29.13","upperLimit":"48.81","value":"39.04"},{"groupId":"OG001","lowerLimit":"44.30","upperLimit":"63.51","value":"54.44"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"105"}],"units":"Participants"}],"description":"DFS rates of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy to receive either two intensive chemotherapy blocks or two 5-week blocks of blinatumomab (HR/IR Randomization). DFS is calculated as the time from randomization to date of first event (treatment failure, relapse, second malignancy, remission death) or date of last contact. Two-year DFS estimates will be calculated from date of randomization for both Arm A and Arm B. Two-sided 95% confidence intervals will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive Block 2 over 4 weeks, Block 3 over 4 weeks, and then undergo allogeneic HSCT if eligible. Patients with persistent testicular involvement after Block 1 receive testicular radiation during the Block 2.","id":"OG000","title":"Arm A (HR and IR Control)"},{"description":"Patients receive Blinatumomab Block 1 over 5 weeks, Blinatumomab Block 2 over 5 weeks, and then undergo allogeneic HSCT if eligible. Patients with persistent testicular involvement after Block 1 receive testicular radiation during the first block of blinatumomab.","id":"OG001","title":"Arm B (HR and IR Blinatumomab)"}],"paramType":"NUMBER","populationDescription":"HR and IR patients randomized per protocol prior to June 30, 2019. This is the cohort of patients who were included in the primary analysis addressing the primary objective on HR/IR patients. Of the total of 216 randomized HR/IR patients, 2 patients with randomization procedure errors and 6 patients randomized after June 30, 2019 were excluded.","reportingStatus":"POSTED","timeFrame":"Up to 2 years from date of randomization","title":"Disease Free Survival (DFS) of High-risk (HR) and Intermediate-risk (IR) Relapse Patients","type":"PRIMARY","unitOfMeasure":"percentage of participants"}